血糖阈值与糖尿病合并COVID-19结局:基于连续血糖监测的回顾性探索性研究
本研究通过间歇性扫描式连续血糖监测(平均10.2天)评估35例糖尿病合并COVID-19患者的血糖水平,计算TAR、TBR、TIR和CV。发现血糖>160 mg/dL、<70 mg/dL及高CV与复合不良结局和住院延长显著相关,提示改善这些血糖指标可能改善预后。
要点
- 血糖>160 mg/dL与糖尿病合并COVID-19不良结局显著相关
- 血糖<70 mg/dL及高变异系数亦与不良结局相关
- 改善血糖控制指标可能改善此类患者预后
核心结论
- 糖尿病合并COVID-19患者血糖>160 mg/dL、<70 mg/dL及高CV增加不良结局风险。
研究设计与样本
- 回顾性探索性研究,35例患者接受间歇性扫描式连续血糖监测,平均10.2天。
主要发现
- 阈值160-200 mg/dL的TAR与复合不良结局显著相关(校正协变量后)。
- TBR(<70 mg/dL)和TIR(70-160 mg/dL)与复合不良结局及住院延长显著相关,而平均传感器葡萄糖水平无显著关联。
- 传感器葡萄糖CV三分位组的多变量校正OR分别为1.00、1.18和25.2。
临床怎么用
- 对糖尿病合并COVID-19患者,应关注血糖>160 mg/dL、<70 mg/dL及高CV,并采取改善这些指标的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although elevated glucose levels are reported to be associated with adverse outcomes of coronavirus disease 2019 (COVID-19), the optimal range of glucose in patients with COVID-19 and diabetes remains unknown. This study aimed to investigate the threshold of glycemia and its association with the outcomes of COVID-19. RESEARCH DESIGN AND METHODS: Glucose levels were assessed through intermittently scanned continuous glucose monitoring in 35 patients for an average period of 10.2 days. The percentages of time above range (TAR), time below range (TBR), time in range (TIR), and coefficient of variation (CV) were calculated. Composite adverse outcomes were defined as either the need for admission to the intensive care unit, need for mechanical ventilation, or morbidity with critical illness. RESULTS: TARs using thresholds from 160 to 200 mg/dL were significantly associated with composite adverse outcomes after adjustment of covariates. Both TBR (<70 mg/dL) and TIR (70-160 mg/dL), but not mean sensor glucose level, were significantly associated with composite adverse outcomes and prolonged hospitalization. The multivariate-adjusted odds ratios of the CV of sensor glucose across tertiles for composite adverse outcomes of COVID-19 were 1.00, 1.18, and 25.2, respectively. CONCLUSIONS: Patients with diabetes and COVID-19 have an increased risk of adverse outcomes with glucose levels >160 mg/dL and <70 mg/dL and a high CV. Therapies that improve these metrics of glycemic control may result in better prognoses for these patients.
引用
- Shen Y, Fan X, Zhang L, et al. Thresholds of Glycemia and the Outcomes of COVID-19 Complicated With Diabetes: A Retrospective Exploratory Study Using Continuous Glucose Monitoring. Diabetes Care. 2021. PMID: 33574126. doi:10.2337/dc20-1448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。